| Literature DB >> 27974821 |
Diane E Halliwell1, Maria Kyrgiou2,3, Anita Mitra2,3, Ilkka Kalliala2,3, Evangelos Paraskevaidis4, Georgios Theophilou5, Pierre L Martin-Hirsch6, Francis L Martin1,7.
Abstract
Local excisional treatment for cervical intra-epithelial neoplasia (CIN) is linked to significant adverse sequelae including preterm birth, with cone depth and radicality of treatment correlating to the frequency and severity of adverse events. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy can detect underlying cervical disease more accurately than conventional cytology. The chemical profile of cells pre- and post-treatment may differ as a result of altered biochemical processes due to excision, or treatment of the disease. Since pre-treatment cervical length varies amongst women, the percentage of cervix excised may correlate more accurately to risk than absolute dimensions. We show that treatment for CIN significantly alters the biochemistry of the cervix, compared with women who have not had treatment; this is due to the removal of cervical tissue rather than the removal of the disease. However, the spectra do not seem to correlate to the cone depth or proportion of cervical length excised. Future research should aim to explore the impact of treatment in a larger cohort.Entities:
Mesh:
Year: 2016 PMID: 27974821 PMCID: PMC5156919 DOI: 10.1038/srep38921
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart of the included population and different comparison groups.
Patient characteristics.
| Characteristics | Comparison 1: Treated women with paired samples | Comparison 2: Normal post-treatment vs. normal untreated controls | Comparison 3: Treated by cone depth/proportion vs. normal untreated controls | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-treatment (n = 29) | Post treatment (n = 33) | Normal post-treatment, (Cytology –ve/HPV –ve) (n = 39) | Normal controls (Cytology –ve/HPV –ve) (n = 20) | Post treatment (n = 58) | Controls (Cytology -ve; HPV status ignored) (n = 27) | ||||
| 0.69 | 0.87 | 0.50 | |||||||
| Mean (SD, range) | 30.3 (5.0, 25–43) | 30.8 (5.0, 25–43) | 30.8 (4.5, 25–43) | 30.6 (4.3, 24–37) | 31.3 (4.4, 25–43) | 30.0 (4.4, 22–37) | |||
| 1.00 | 0.12 | 0.24 | |||||||
| Caucasian | 22/29 (76) | 25/33 (76) | 30/39 (77) | 11/20 (55) | 46/58 (79) | 18/27 (67) | |||
| Asian | 5/29 (17) | 6/33 (18) | 6/39 (15) | 4/20 (20) | 8/58 (14) | 4/27 (15) | |||
| Black | 2/29 (7) | 2/33 (6) | 3/39 (8) | 5/20 (25) | 4/58 (7) | 5/27 (18) | |||
| 0.77 | 0.18 | ||||||||
| Non-smoker | 23/29 (79) | 25/33 (76) | 27/39 (69) | 19/20 (95) | 41/58 (71) | 23/27 (85) | |||
| Current smoker | 6/29 (21) | 8/33 (24) | 12/39 (31) | 1/20 (5) | 17/58 (29) | 4/27 (15) | |||
| 0.98 | 0.05 | 0.06 | |||||||
| Nil | 11/29 (37) | 11/33 (33) | 10/39 (25) | 13/20 (65) | 16/58 (28) | 16/27 (59) | |||
| Condoms | 1/29 (4) | 2/33 (6) | 6/39 (15) | 2/20 (10) | 8/58 (14) | 4/27 (15) | |||
| COCP | 14/29 (48) | 17/33 (52) | 20/39 (51) | 3/20 (15) | 28/58 (48) | 4/27 (15) | |||
| POP | 2/29 (7) | 2/33 (6) | 1/39 (3) | 1/20 (5) | 2/58 (3) | 1/27 (4) | |||
| Implant | 0/20 (0) | 0/33 (0) | 0/39 (0) | 0/20 (0) | 0/58 (0) | 1/27 (4) | |||
| Mirena IUS | 1/29 (4) | 1/33 (3) | 1/39 (3) | 1/20 (5) | 2/58 (3) | 1/27 (4) | |||
| Copper IUD | 0/29 (0) | 0/33 (0) | 0/39 (0) | 0/20 (0) | 1/58 (2) | 0/27 (0) | |||
| Vaginal ring | 0/29 (0) | 0/33 (0) | 1/39 (3) | 0/20 (0) | 1/58 (2) | 0/27 (0) | |||
| 1.00 | 0.52 | 0.51 | |||||||
| Nulliparous | 21/29 (72) | 24/33 (73) | 32/39 (82) | 15/20 (75) | 45/58 (78) | 22/27 (81) | |||
| Parous | 8/29 (28) | 9/33 (27) | 7/39 (18) | 5/20 (25) | 13/58 (22) | 5/27 (19) | |||
| 0.71 | 0.28 | 0.31 | |||||||
| >48 hours | 26/29 (90) | 28/33 (85) | 34/39 (87) | 15/20 (75) | 52/58 (90) | 22/27 (81) | |||
| <48 hours | 3/29 (10) | 5/33 (15) | 5/39 (13) | 5/20 (25) | 6/58 (10) | 5/27 (19) | |||
| 0.40 | 0.14 | 0.08 | |||||||
| Luteal | 15/29 (52) | 18/33 (55) | 21/39 (54) | 6/20 (30) | 29/58 (50) | 7/27 (26) | |||
| Follicular | 13/29 (45) | 11/33 (33) | 14/39 (36) | 9/20 (45) | 23/58 (40) | 14/27 (52) | |||
| Unknown | 1/29 (3) | 4/33 (12) | 4/39 (10) | 5/20 (25) | 6/58 (10) | 6/27 (22) | |||
| 0.61 | 0.92 | 0.37 | |||||||
| <4.5 | 12/29 (41) | 13/33 (39) | 16/39 (41) | 9/20 (45) | 24/58 (41) | 15/27 (56) | |||
| ≥4.5 | 16/29 (55) | 20/33 (61) | 21/39 (54) | 9/20 (45) | 31/58 (53) | 10/27 (37) | |||
| Unknown | 1/29 (4) | 0/33 (0) | 2/39 (5) | 2/20 (10) | 3/58 (6) | 2/27 (7) | |||
| 1.00 | 0.13 | 0.16 | |||||||
| No | 27/29 (93) | 31/33 (94) | 35/39 (89) | 15/20 (75) | 52/58 (90) | 21/27 (78) | |||
| Yes | 2/29 (7) | 2/33 (6) | 3/39 (8) | 2/20 (10) | 5/58 (8) | 3/27 (11) | |||
| Unknown | 0/29 (0) | 0/33 (0) | 1/39 (3) | 3/20 (15) | 1/58 (2) | 3/27 (11) | |||
| 1.00 | 0.59 | ||||||||
| Negative | 1/29 (4) | 27/33 (82) | 39/39 (100) | 20/20 (100) | 46/58 (79) | 20/27 (74) | |||
| Positive | 28/29 (96)a | 6/33 (18) | 0/39 (0) | 0/20 (0) | 12/58 (21) | 7/27 (26)b | |||
aTwo patients with ‘unclear’ results were included in this group; b Two patients with ‘unknown’ results were included in this group. COCP: Combined oral contraceptive pill; HPV: Human Papillomavirus; HSIL: High-grade intraepithelial lesion; IUD: Intrauterine device; IUS: Intrauterine system; -ve: Negative; POP: Progesterone-only pill; SD: Standard deviation.
Figure 2PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: Pre- vs Post-treatment (a) together with absorbance per wavenumber (b). The paired samples pre- and post-treatment were significantly different along LD1 (Mean/SD (a): 0.004/0.10 for ‘A’; −0.12/0.08 for ‘B’; p < 0.0001, 95% CI = −0.17 to −0.08). Absorbance associated with lipids, glycomaterials and proteins was shown to have a significant positive rate of change for the pre-treatment group compared with the post-treatment group, indicating their higher bioavailability. Similarly, absorbance associated Amide I and Amide II was shown to have a significant positive rate of change for the post-treatment group compared within the pre-treatment group. Absorbance associated with glycogen, collagen and symmetric phosphate of DNA was shown to have a significant negative rate of change for the pre-treatment group compared with the post-treatment group, suggesting lower bioavailability. Similarly, absorbance associated asymmetric phosphate for DNA was shown to have a significant negative rate of change for the post-treatment group compared with the pre-treatment group (b). ATR-FTIR: Attenuated total reflection Fourier-transform Infrared; CI: Confidence interval; LD1: Linear Discriminant 1; PCA-LDA: Principal Component Analysis coupled to Linear Discriminant Analysis; SD: Standard deviation.
Figure 3PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: controls vs treated (normal cytology and HPV –ve); (a) together with absorbance per wavenumber (b). The 2 groups were significantly different along LD1 (Mean/SD (a): 0.32/0.10 for Controls; 0.20/0.11 for Treated; p < 0.0001, 95% CI = −0.18 to −0.07). These results evidence that the difference in LD1 was due to the impact of treatment. Absorbance associated with Amide II was shown to have a significant positive rate of change for the treated group compared with controls, indicating higher bioavailability (b). No other significant changes were detected. ATR-FTIR: Attenuated total reflection Fourier-transform Infrared; CI: Confidence interval; LD1: Linear Discriminant 1; -ve: Negative; PCA-LDA: Principal Component Analysis coupled to Linear Discriminant Analysis; +ve: Positive; SD: Standard deviation.
Figure 4PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: Healthy Cervix vs. Cone Depth (a) together with absorbance per wavenumber (b). Mean/SD (a) for each group was: 0.22/0.07 for healthy cervix; 0.15/0.07 for <10 mm; 0.19/0.07 for 10–14 mm; 0.13/0.04 for ≥15 mm. A significant difference along LD1 was detected for healthy cervix vs. <10 mm (p = 0.0008; 95 CI = 0.03 to 0.12); and for healthy cervix vs. ≥15 mm (p = 0.001; 95 CI = 0.03 to 0.15). No significant difference along LD1 was detected for healthy cervix vs. 10–14 mm (p = 0.13; 95 CI = −0.01 to 0.08). Absorbance associated with Amide II was shown to have a significant positive rate of change for <10 mm group compared with healthy cervix, indicating higher bioavailability (b). Similarly, absorbance associated with Amide I and II were shown to have a significant positive rate of change for ≥15 mm compared with healthy cervix, whilst absorbance associated with DNA was shown to have a negative rate of change, indicating lower bioavailability. ATR-FTIR: Attenuated total reflection Fourier-transform Infrared; CI: Confidence interval; LD1: Linear Discriminant 1; PCA-LDA: Principal Component Analysis coupled to Linear Discriminant Analysis; SD: Standard deviation.
Figure 5PCA-LDA scores plot of ATR-FTIR spectra with regards to LD1: Healthy Cervix vs. Percentage Excision (a) together with absorbance per wavenumber (b). Mean/SD (a) for each group was: 0.30/0.07 for healthy cervix; 0.16/0.12 for 11–20%; 0.24/0.06 for 21–30%; 0.22/0.09 for 31–40%; 0.21/0.07 for >40%. A significant difference along LD1 was detected for healthy cervix vs. 11–20% (p = 0.002; mean rank difference: 31.11); for healthy cervix vs. 21–30% (p = 0.03; mean rank difference: 17.85); for healthy cervix vs. 31–40% (p = 0.007; mean rank difference 23.33; and for healthy cervix vs. >40% (p = 0.023; mean rank difference: 27.24). Absorbance associated with lipids and Amide II was shown to have a significant positive rate of change for 11–20% compared with healthy cervix, indicating higher bioavailability (b). No other significant differences were detected for healthy cervix vs. all other groups. ATR-FTIR: Attenuated total reflection Fourier-transform Infrared; CI: Confidence interval; LD1: Linear Discriminant 1; PCA-LDA: Principal Component Analysis coupled to Linear Discriminant Analysis; SD: Standard deviation.